This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Heterogeneous nuclear ribonucleoprotein H.
Inhibits, together with CUGBP1, insulin receptor (IR) pre-mRNA exon 11 inclusion in myoblast. Binds to the IR RNA.
Human | |
---|---|
Gene Name: | HNRNPH1 |
Uniprot: | P31943 |
Entrez: | 3187 |
Belongs to: |
---|
No superfamily |
DKFZp686A15170; heterogeneous nuclear ribonucleoprotein H; heterogeneous nuclear ribonucleoprotein H1 (H); hnRNP H; HNRPH; HNRPH1hnRNPH
Mass (kDA):
49.229 kDA
Human | |
---|---|
Location: | 5q35.3 |
Sequence: | 5; NC_000005.10 (179614178..179634784, complement) |
Expressed ubiquitously.
Nucleus, nucleoplasm.
HNRNPh2, which is a member of heterogeneous nuclearribonucleoproteins, may be familiar to you if you are interested in CML research. This protein inhibits cell proliferation and regulates the PI3K/AKT signaling pathway. You may also have heard of this protein as a biomarker for this disease. Its potential properties and use may be something you want to consider if you are looking at it as a possible biomarker.
HNRNPh2 and other RNA binding proteins are key modulators of cancers. Although HNRNPh2’s function in chronic Myeloid Leukemia (CML), remains unknown, upregulation of its expression was associated with the development of the disease. HNRNPh2 was knocked down in CML cells. This inhibited cell proliferation and promoted death. Furthermore, knockdown of HNRNPh2 in CML cells increased their sensitivity to the drug imatinib.
Boster Bio's HNRNPh2 kit was used for RNA-seq experiments. The cells were prepared, treated with lysis buffer, then 80% were used to perform immunoprecipitation experiments in the presence of HNRNPh2 protein. The remaining 10% cells were used in an immunoprecipitation experiment utilizing rabbit IgG. TRIzol reagent was used to isolate RNA from both IP and input samples. Next, RNA was extracted and analyzed by conventional RTPCR.
Multiple tests were performed to validate the Boster Bio HNRNPh2 anti-body. It conforms to the data sheet specifications. Therefore, you can use it with confidence. If you're looking for an HNRNPh2 antibody, contact Boster Bio. They will meet all specifications. Boster antibodies can be used at any time and are available for sale.
HNRNPh2 controls PI3K/AKT's activity in cancer cells. Activation of PI3K/AKT can be crucial for cell survival and growth. A mutation in this gene may cause cell death. HNRNPh2 interferes with the activity of this pathway through inhibition of PTPN6, a binding Protein of P210 BCCR-ABL. HNRNPh2 functions are not known, but it may be worth further investigation.
The regulation of cell proliferation, apoptosis, and angiogenesis is dependent on Akt signaling. The Akt pathway controls phosphoinositide-3kinase, which phosphorylates many proteins involved in cell proliferation and growth. Akt regulates cell adhesion, metabolism and angiogenesis.
Researchers have identified HNRNPh2 a regulator in the PI3K/AKT pathway of cancer cells. They used RIPPCR, agarose gel electrophoresis and PCR to study the interaction between HNRNPh2 & PTPN6. They also used the KEGG pathway enrichment method to identify the main signal transduction pathways and biochemical metabolic pathways that involve HNRNPh2. CML cells were transfected using sh-HNRNPh2 and PTPN6 overexpression plasmids. Western blot analysis was used to determine the levels of PTPN6 proteins.
HNRNPh2 regulates the PI3K/AKT pathway and has the ability to cross between cell types. Akt also promotes the phosphorylation Ser-133 CREB of CREB which promotes the recruitment and transcription co-activator proteins CBP and genes with CREs. These results support the notion that HNRNPh2 regulates PI3K/AKT pathway is an important regulator of cell development and function.
A recent study found that downregulation of HNRNPh2 inhibits cell proliferation and increases cell death. These results indicate that the downregulation of this protein can prevent or reverse some types of disease. These findings will require further research. These inhibitors, therefore, are still in development. However, they do have many promising features. Read on to learn more about them. Here's a look at their potential applications for treating cancer.
Researchers discovered that HNRNPh2 binds to the PTPN6 mRNA, which is required for the activation of PI3K/AKT. HNRNPh2 also regulates the PTPN6 pathway which is crucial for CML development. It is possible to target the HNRNPh2 – PTPN6 axis as a promising therapeutic strategy.
The study was carried out with the HeLa cervical cancer cell line and ten breast cancer cell lines. Cells were cultured in DMEM or RPMI-1640 containing 10% FBS. Puromycin, 2 mg/ml, was added to the culture media to screen for stably-transfected cells. The HNRNPh2 inhibitors inhibit cell proliferation in a number of cancer cell types, according to the results.
Boster Bio HNRNPh2 also inhibits cell proliferation and growth in many types of cancers, including pancreatic. The inhibitor blocks the activation of Tsc1/mTOR, Gadd45g/Stat3, and IL-17A. Its inhibitory effects on these cellular processes will allow the therapy to be used in a variety of clinical trials.
A new study has identified HNRNPh2 a potential biomarker in CML. Although the gene has been studied in a variety of cancers it has never been tested in CML patients. Its decreased expression could be due to abnormalities in the MAPK and BCR/ABL signaling pathways. These findings do not necessarily mean that HNRNPh2 can be used as a biomarker for CML.
Researchers used NGS to identify several miRNAs that could help in the diagnosis of CML and their treatment. Among these, the hsa–miR-181a-5p miRNA may be a novel one with therapeutic potential against BCR–ABL1.
Studies on human tumours have shown that altered expressions (RBPs), of RNA-binding genes (RBPs), are associated with disease progression. In CML patients with blast phase disease, HNRNPh2 mRNA levels were significantly higher than in healthy controls. CML cells also showed an increase in the sensitivity to imatinib by knocking down HNRNPh2.
Researchers first explored the expression of HNRNPh2 in BM-MNCs of patients with CML and healthy donors. HNRNPh2 was detected in CML patients by qRT-PCR. HNRNPh2's mRNA levels were higher in the chronic phase and the progressing phase of CML, while the blast phase had the highest levels. Researchers then measured the levels HNRNPh2 proteins in 10 patients with CML.
Boster Bio's HNRNPh2 antibody marker has been widely used for immunoprecipitation. This product is an engineered-recombinant, high-affinity antigen binding protein. It is used with the protein A/G antibodies in immunoprecipitation. This allows the antibody can be incubated in the beads with a slurry.
Cell lysis buffer was applied to the cells. The lysis sample was used for immunoprecipitation using the HNRNPh2 antibody as a positive control and 10% with rabbit IgG to make up the remaining 80%. The purified RNA were then analyzed by conventional RTPCR. This was repeated twice for each type marker.
The HNRNPh2 protein can also be found in the cytoplasm via RT-PCR. PTPN6 can also regulate activity of the PI3K/AKT pathway. HNRNPh2 is responsible for regulating the PI3K/AKT path, so it may be useful in targeting the PI3K/AKT path to combat CML.
To validate this marker, we used a cell culture model that showed the mRNA level of PTPN6. The HNRNPh2 protein marker was found physical binding to the mRNA. It pulled it down. This interaction led to differential expression of genes in the PI3K/AKT pathway. This finding suggests that HNRNPh2 is a novel therapeutic target in the treatment of CML.
Autophagy is controlled by the HNRNPh2 gene. It may be possible to stop the disease progression by downregulating this gene. Further research is needed in order to confirm this hypothesis. A combination therapy may also prove necessary, since downregulation of this gene is crucial for CML progression to remission. This will allow us to better understand the autophagy-associated transcriptome landscape.
HNRNPh2 is an essential RNA-binding protein, which regulates gene expression directly by binding to mRNA. In studies that were done previously, PTPN6 had an impact on the PI3K/AKT pathway. HNRNPh2 could be used to target the PI3K/AKT pathway.
The HNRNPh2 is an upstream regulatory gene for the PTPN6. The HNRNPh2 gene binds to PTPN6 mRNA which inhibits cell proliferation. Moreover, it regulates PTPN6 protein expression. HNRNPh2 is a clinical translational tool with tremendous clinical value. HNRNPh2 & PTPN6 both play a critical role for CML progression.
The company produces ELISA kit and research antibodies for detecting and diagnosing cancer, neurological disorders, inflammation, and developmental biology. The antibodies have been tested against 250 tissue samples to validate their immunogen design. Their antibodies are highly specific with high affinity. In addition, they can be used quantitatively against known quantities of recombinant proteins.
PMID: 7499401 by Honore B., et al. Heterogeneous nuclear ribonucleoproteins H, H', and F are members of a ubiquitously expressed subfamily of related but distinct proteins encoded by genes mapping to different chromosomes.
PMID: 7512260 by Matunis M.J., et al. The hnRNP F protein: unique primary structure, nucleic acid-binding properties, and subcellular localization.